Fisher Asset Management LLC Has $16.80 Million Stock Holdings in Merit Medical Systems, Inc. (NASDAQ:MMSI)

Fisher Asset Management LLC reduced its position in Merit Medical Systems, Inc. (NASDAQ:MMSI) by 6.7% in the 4th quarter, HoldingsChannel reports. The firm owned 221,205 shares of the medical instruments supplier’s stock after selling 16,007 shares during the period. Fisher Asset Management LLC’s holdings in Merit Medical Systems were worth $16,803,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. William Blair Investment Management LLC increased its holdings in shares of Merit Medical Systems by 15.4% during the 3rd quarter. William Blair Investment Management LLC now owns 3,895,695 shares of the medical instruments supplier’s stock worth $268,881,000 after acquiring an additional 520,423 shares during the last quarter. abrdn plc acquired a new stake in shares of Merit Medical Systems during the 3rd quarter worth about $24,446,000. Loomis Sayles & Co. L P boosted its holdings in shares of Merit Medical Systems by 25.9% during the 3rd quarter. Loomis Sayles & Co. L P now owns 1,031,173 shares of the medical instruments supplier’s stock worth $71,172,000 after buying an additional 212,256 shares during the period. Comerica Bank acquired a new position in Merit Medical Systems in the 3rd quarter valued at about $14,022,000. Finally, Walleye Capital LLC bought a new position in Merit Medical Systems in the 3rd quarter valued at about $8,782,000. Institutional investors own 99.66% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Raul Jr. Parra sold 6,480 shares of Merit Medical Systems stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $73.95, for a total value of $479,196.00. Following the transaction, the chief financial officer now owns 12,007 shares in the company, valued at approximately $887,917.65. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, Director Thomas James Gunderson sold 18,157 shares of the stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $76.03, for a total value of $1,380,476.71. Following the completion of the transaction, the director now owns 19,257 shares of the company’s stock, valued at approximately $1,464,109.71. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Raul Jr. Parra sold 6,480 shares of the business’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $73.95, for a total transaction of $479,196.00. Following the sale, the chief financial officer now directly owns 12,007 shares in the company, valued at approximately $887,917.65. The disclosure for this sale can be found here. Insiders sold 49,637 shares of company stock worth $3,751,673 over the last three months. Insiders own 3.70% of the company’s stock.

Analysts Set New Price Targets

MMSI has been the topic of several research reports. Barrington Research upped their target price on Merit Medical Systems from $98.00 to $100.00 and gave the company an “outperform” rating in a research report on Wednesday, May 1st. Needham & Company LLC decreased their price objective on Merit Medical Systems from $88.00 to $85.00 and set a “buy” rating on the stock in a report on Wednesday, May 1st. CL King initiated coverage on Merit Medical Systems in a research report on Thursday, April 11th. They set a “buy” rating and a $88.00 price objective on the stock. Canaccord Genuity Group reduced their target price on shares of Merit Medical Systems from $112.00 to $102.00 and set a “buy” rating for the company in a research report on Wednesday, May 1st. Finally, Oppenheimer upped their price target on shares of Merit Medical Systems from $82.00 to $87.00 and gave the company an “outperform” rating in a research note on Thursday, February 29th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $92.78.

Merit Medical Systems Stock Up 2.5 %

Shares of NASDAQ MMSI opened at $78.97 on Monday. Merit Medical Systems, Inc. has a 52 week low of $62.58 and a 52 week high of $85.62. The stock’s fifty day moving average is $74.19 and its 200 day moving average is $74.21. The company has a debt-to-equity ratio of 0.65, a quick ratio of 4.38 and a current ratio of 6.03. The stock has a market capitalization of $4.59 billion, a P/E ratio of 45.39, a PEG ratio of 2.20 and a beta of 0.91.

Merit Medical Systems (NASDAQ:MMSI) last released its earnings results on Tuesday, April 30th. The medical instruments supplier reported $0.77 EPS for the quarter, beating the consensus estimate of $0.71 by $0.06. Merit Medical Systems had a net margin of 7.94% and a return on equity of 15.02%. The firm had revenue of $323.51 million for the quarter, compared to analyst estimates of $315.57 million. During the same period last year, the firm earned $0.64 EPS. The business’s quarterly revenue was up 8.7% compared to the same quarter last year. Sell-side analysts forecast that Merit Medical Systems, Inc. will post 3.33 earnings per share for the current fiscal year.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.